North American Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker, and Protein Biomarker), by Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Other), by Applications (Drug Discovery and Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period 2019-2025.
North American cancer biomarker market is growing at a CAGR of around 11.8% during the forecast period. The North American market for cancer biomarker is a significant market and is analyzed on the basis of country as the US and Canada. Factors that are contributing significantly in the market growth includes research and development, and high healthcare expenditure and so on. Moreover, rising number of cancer patients are considered to be one of the major factors that are driving the growth of North American cancer biomarker market.
Accordingly, the expenditure rate of the US is more than that of Canada as the US government invests more on research and development and there is more business opportunity in the US as compared to Canada. The major factors that are driving the North American cancer biomarker market includes rising healthcare spending, R&D investments, high quality of healthcare infrastructure and demand for personalized medicine in the region. The change in lifestyle is also a major factor that increases the possibilities of cancer in North America such as inadequate diet, consumption of alcohol and smoking. For example, as per the Chief Public Health Officer’s (CPHO) Report 2015, an estimated 22 million Canadians representing almost 80% of the population consumed alcohol in 2013. About 4.4 million Canadians consumed alcohol that could lead to many fatal diseases, such as various forms of cancer.
The rising healthcare expenditure can have an important role in the development of the cancer-based therapies and personalized drugs. Moreover, according to the National Cancer Institute in 2017, estimated national expenditures for cancer care in the US was $147.3 billion. In the future, this cost is expected to increase with the aging population coupled with increasing cancer prevalence. It is also expected to increase with the adoption of new and often more expensive treatments as standards of care, thus contributing towards the growth of the North American cancer biomarker market growth.
Research Methodology:
The market study of the North American cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. North American Cancer Biomarker Market Research and Analysis by Biomarker Type
2. North American Cancer Biomarker Market Research and Analysis by Cancer Type
3. North American Cancer Biomarker Market Research and Analysis by Application
4. North American Cancer Biomarker Market Research and Analysis by Profiling Technology
The Report Covers:
North American cancer biomarker market is growing at a CAGR of around 11.8% during the forecast period. The North American market for cancer biomarker is a significant market and is analyzed on the basis of country as the US and Canada. Factors that are contributing significantly in the market growth includes research and development, and high healthcare expenditure and so on. Moreover, rising number of cancer patients are considered to be one of the major factors that are driving the growth of North American cancer biomarker market.
Accordingly, the expenditure rate of the US is more than that of Canada as the US government invests more on research and development and there is more business opportunity in the US as compared to Canada. The major factors that are driving the North American cancer biomarker market includes rising healthcare spending, R&D investments, high quality of healthcare infrastructure and demand for personalized medicine in the region. The change in lifestyle is also a major factor that increases the possibilities of cancer in North America such as inadequate diet, consumption of alcohol and smoking. For example, as per the Chief Public Health Officer’s (CPHO) Report 2015, an estimated 22 million Canadians representing almost 80% of the population consumed alcohol in 2013. About 4.4 million Canadians consumed alcohol that could lead to many fatal diseases, such as various forms of cancer.
The rising healthcare expenditure can have an important role in the development of the cancer-based therapies and personalized drugs. Moreover, according to the National Cancer Institute in 2017, estimated national expenditures for cancer care in the US was $147.3 billion. In the future, this cost is expected to increase with the aging population coupled with increasing cancer prevalence. It is also expected to increase with the adoption of new and often more expensive treatments as standards of care, thus contributing towards the growth of the North American cancer biomarker market growth.
Research Methodology:
The market study of the North American cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. North American Cancer Biomarker Market Research and Analysis by Biomarker Type
2. North American Cancer Biomarker Market Research and Analysis by Cancer Type
3. North American Cancer Biomarker Market Research and Analysis by Application
4. North American Cancer Biomarker Market Research and Analysis by Profiling Technology
The Report Covers:
- Comprehensive Research Methodology of the North American Cancer biomarker market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the North American Cancer biomarker market.
- Insights about market determinants which are stimulating the North American Cancer biomarker market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories Inc.
- Astellas Pharma Inc.
- Becton, Dickson and Co.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- F. Hoffmann-La Roche Ltd.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.
